Cost-effectiveness of RespiGam at a University Teaching Hospital

To the Editor. Introduction of respiratory syncytial virus immune globulin (RSV-IG) (RespiGam, Medimmune) earlier this year for the prevention of RSV lower respiratory tract infections (LRI) in infants led us to evaluate RespiGam for use at our university teaching hospital. If the Food and Drug Administration (FDA)-approved guidelines for RespiGam were followed, we identified two potential problems. First, a high cost would be incurred at institutions with many eligible neonates. Second, the administration of intravenous medications like RSV-IG is not routinely performed in outpatient clinics, and guidelines and resources would need to be allocated to deliver the RSV-IG over the 3- to 4-hour administration time. To determine the cost-effectiveness of RSV-IG at …